

for predicting or treating testostosis

This section reports a thymine precursor for site for the formation of telomeric units (pTNA) and is cleaved by a telomerase at position 18 and by a hammerhead ribzyme at position 2. These thymosins are being studied for their ability to inhibit the activity of a growth factor (e.g. pTNA) responsible for abnormal growth of cells (SM) proliferation in vascular tissue leading to restenosis. The thymosins can also directly block the production of endothelial cell regulatory factors involved with the growth of blood vessels and injury.

$$Z = \{1, 2, \dots, n\}, \quad A = \{1, 2, \dots, n\}, \quad B = \{1, 2, \dots, n\}, \quad C = \{1, 2, \dots, n\}, \quad D = \{1, 2, \dots, n\}, \quad E = \{1, 2, \dots, n\}, \quad F = \{1, 2, \dots, n\}, \quad G = \{1, 2, \dots, n\}, \quad H = \{1, 2, \dots, n\}, \quad I = \{1, 2, \dots, n\}, \quad J = \{1, 2, \dots, n\}, \quad K = \{1, 2, \dots, n\}, \quad L = \{1, 2, \dots, n\}, \quad M = \{1, 2, \dots, n\}, \quad N = \{1, 2, \dots, n\}, \quad O = \{1, 2, \dots, n\}, \quad P = \{1, 2, \dots, n\}, \quad Q = \{1, 2, \dots, n\}, \quad R = \{1, 2, \dots, n\}, \quad S = \{1, 2, \dots, n\}, \quad T = \{1, 2, \dots, n\}, \quad U = \{1, 2, \dots, n\}, \quad V = \{1, 2, \dots, n\}, \quad W = \{1, 2, \dots, n\}, \quad X = \{1, 2, \dots, n\}, \quad Y = \{1, 2, \dots, n\}, \quad Z = \{1, 2, \dots, n\}.$$

entry Match: 100.00; Score: 16; 18; Length: 16;
Post Local Similarity: 100.00; Prev. No.: 100.00;
Match: 100.00; Match: 100.00; Match: 100.00

[illegible]

1. $AA \rightarrow A$
 2. $AA \rightarrow A$
 3. $AA \rightarrow A$
 4. $AA \rightarrow A$
 5. $AA \rightarrow A$
 6. $AA \rightarrow A$
 7. $AA \rightarrow A$
 8. $AA \rightarrow A$
 9. $AA \rightarrow A$
 10. $AA \rightarrow A$
 11. $AA \rightarrow A$
 12. $AA \rightarrow A$
 13. $AA \rightarrow A$
 14. $AA \rightarrow A$
 15. $AA \rightarrow A$
 16. $AA \rightarrow A$
 17. $AA \rightarrow A$
 18. $AA \rightarrow A$
 19. $AA \rightarrow A$
 20. $AA \rightarrow A$
 21. $AA \rightarrow A$
 22. $AA \rightarrow A$
 23. $AA \rightarrow A$
 24. $AA \rightarrow A$
 25. $AA \rightarrow A$
 26. $AA \rightarrow A$
 27. $AA \rightarrow A$
 28. $AA \rightarrow A$
 29. $AA \rightarrow A$
 30. $AA \rightarrow A$
 31. $AA \rightarrow A$
 32. $AA \rightarrow A$
 33. $AA \rightarrow A$
 34. $AA \rightarrow A$
 35. $AA \rightarrow A$
 36. $AA \rightarrow A$
 37. $AA \rightarrow A$
 38. $AA \rightarrow A$
 39. $AA \rightarrow A$
 40. $AA \rightarrow A$
 41. $AA \rightarrow A$
 42. $AA \rightarrow A$
 43. $AA \rightarrow A$
 44. $AA \rightarrow A$
 45. $AA \rightarrow A$
 46. $AA \rightarrow A$
 47. $AA \rightarrow A$
 48. $AA \rightarrow A$
 49. $AA \rightarrow A$
 50. $AA \rightarrow A$
 51. $AA \rightarrow A$
 52. $AA \rightarrow A$
 53. $AA \rightarrow A$
 54. $AA \rightarrow A$
 55. $AA \rightarrow A$
 56. $AA \rightarrow A$
 57. $AA \rightarrow A$
 58. $AA \rightarrow A$
 59. $AA \rightarrow A$
 60. $AA \rightarrow A$
 61. $AA \rightarrow A$
 62. $AA \rightarrow A$
 63. $AA \rightarrow A$
 64. $AA \rightarrow A$
 65. $AA \rightarrow A$
 66. $AA \rightarrow A$
 67. $AA \rightarrow A$
 68. $AA \rightarrow A$
 69. $AA \rightarrow A$
 70. $AA \rightarrow A$
 71. $AA \rightarrow A$
 72. $AA \rightarrow A$
 73. $AA \rightarrow A$
 74. $AA \rightarrow A$
 75. $AA \rightarrow A$
 76. $AA \rightarrow A$
 77. $AA \rightarrow A$
 78. $AA \rightarrow A$
 79. $AA \rightarrow A$
 80. $AA \rightarrow A$
 81. $AA \rightarrow A$
 82. $AA \rightarrow A$
 83. $AA \rightarrow A$
 84. $AA \rightarrow A$
 85. $AA \rightarrow A$
 86. $AA \rightarrow A$
 87. $AA \rightarrow A$
 88. $AA \rightarrow A$
 89. $AA \rightarrow A$
 90. $AA \rightarrow A$
 91. $AA \rightarrow A$
 92. $AA \rightarrow A$
 93. $AA \rightarrow A$
 94. $AA \rightarrow A$
 95. $AA \rightarrow A$
 96. $AA \rightarrow A$
 97. $AA \rightarrow A$
 98. $AA \rightarrow A$
 99. $AA \rightarrow A$
 100. $AA \rightarrow A$

1. **Author(s):**
 2. **Title:**
 3. **Journal:**
 4. **Volume:**
 5. **Issue:**
 6. **Year:**
 7. **Pages:**
 8. **Abstract:**
 9. **Keywords:**
 10. **Notes:**
 11. **References:**
 12. **Index:**
 13. **Subject:**
 14. **Classification:**
 15. **Language:**
 16. **Country:**
 17. **City:**
 18. **State:**
 19. **Zip:**
 20. **Phone:**
 21. **Fax:**
 22. **E-mail:**
 23. **Web:**
 24. **Other:**
 25. **Comments:**
 26. **Remarks:**
 27. **Signature:**
 28. **Date:**
 29. **Time:**
 30. **Place:**
 31. **Country:**
 32. **City:**
 33. **State:**
 34. **Zip:**
 35. **Phone:**
 36. **Fax:**
 37. **E-mail:**
 38. **Web:**
 39. **Other:**
 40. **Comments:**
 41. **Remarks:**
 42. **Signature:**
 43. **Date:**
 44. **Time:**
 45. **Place:**
 46. **Country:**
 47. **City:**
 48. **State:**
 49. **Zip:**
 50. **Phone:**
 51. **Fax:**
 52. **E-mail:**
 53. **Web:**
 54. **Other:**
 55. **Comments:**
 56. **Remarks:**
 57. **Signature:**
 58. **Date:**
 59. **Time:**
 60. **Place:**
 61. **Country:**
 62. **City:**
 63. **State:**
 64. **Zip:**
 65. **Phone:**
 66. **Fax:**
 67. **E-mail:**
 68. **Web:**
 69. **Other:**
 70. **Comments:**
 71. **Remarks:**
 72. **Signature:**
 73. **Date:**
 74. **Time:**
 75. **Place:**
 76. **Country:**
 77. **City:**
 78. **State:**
 79. **Zip:**
 80. **Phone:**
 81. **Fax:**
 82. **E-mail:**
 83. **Web:**
 84. **Other:**
 85. **Comments:**
 86. **Remarks:**
 87. **Signature:**
 88. **Date:**
 89. **Time:**
 90. **Place:**
 91. **Country:**
 92. **City:**
 93. **State:**
 94. **Zip:**
 95. **Phone:**
 96. **Fax:**
 97. **E-mail:**
 98. **Web:**
 99. **Other:**
 100. **Comments:**
 101. **Remarks:**
 102. **Signature:**
 103. **Date:**
 104. **Time:**
 105. **Place:**
 106. **Country:**
 107. **City:**
 108. **State:**
 109. **Zip:**
 110. **Phone:**
 111. **Fax:**
 112. **E-mail:**
 113. **Web:**
 114. **Other:**
 115. **Comments:**
 116. **Remarks:**
 117. **Signature:**
 118. **Date:**
 119. **Time:**
 120. **Place:**
 121. **Country:**
 122. **City:**
 123. **State:**
 124. **Zip:**
 125. **Phone:**
 126. **Fax:**
 127. **E-mail:**
 128. **Web:**
 129. **Other:**
 130. **Comments:**
 131. **Remarks:**
 132. **Signature:**
 133. **Date:**
 134. **Time:**
 135. **Place:**
 136. **Country:**
 137. **City:**
 138. **State:**
 139. **Zip:**
 140. **Phone:**
 141. **Fax:**
 142. **E-mail:**
 143. **Web:**
 144. **Other:**
 145. **Comments:**
 146. **Remarks:**
 147. **Signature:**
 148. **Date:**
 149. **Time:**
 150. **Place:**
 151. **Country:**
 152. **City:**
 153. **State:**
 154. **Zip:**
 155. **Phone:**
 156. **Fax:**
 157. **E-mail:**
 158. **Web:**
 159. **Other:**
 160. **Comments:**
 161. **Remarks:**
 162. **Signature:**
 163. **Date:**
 164. **Time:**
 165. **Place:**
 166. **Country:**
 167. **City:**
 168. **State:**
 169. **Zip:**
 170. **Phone:**
 171. **Fax:**
 172. **E-mail:**
 173. **Web:**
 174. **Other:**
 175. **Comments:**
 176. **Remarks:**
 177. **Signature:**
 178. **Date:**
 179. **Time:**
 180. **Place:**
 181. **Country:**
 182. **City:**
 183. **State:**
 184. **Zip:**
 185. **Phone:**
 186. **Fax:**
 187. **E-mail:**
 188. **Web:**
 189. **Other:**
 190. **Comments:**
 191. **Remarks:**
 192. **Signature:**
 193. **Date:**
 194. **Time:**
 195. **Place:**
 196. **Country:**
 197. **City:**
 198. **State:**
 199. **Zip:**
 200. **Phone:**
 201. **Fax:**
 202. **E-mail:**
 203. **Web:**
 204. **Other:**
 205. **Comments:**
 206. **Remarks:**
 207. **Signature:**
 208. **Date:**
 209. **Time:**
 210. **Place:**
 211. **Country:**
 212. **City:**
 213. **State:**
 214. **Zip:**
 215. **Phone:**
 216. **Fax:**
 217. **E-mail:**
 218. **Web:**
 219. **Other:**
 220. **Comments:**
 221. **Remarks:**
 222. **Signature:**
 223. **Date:**
 224. **Time:**
 225. **Place:**
 226. **Country:**
 227. **City:**
 228. **State:**
 229. **Zip:**
 230. **Phone:**
 231. **Fax:**
 232. **E-mail:**
 233. **Web:**
 234. **Other:**
 235. **Comments:**
 236. **Remarks:**
 237. **Signature:**
 238. **Date:**
 239. **Time:**
 240. **Place:**
 241. **Country:**
 242. **City:**
 243. **State:**
 244. **Zip:**
 245. **Phone:**
 246. **Fax:**
 247. **E-mail:**
 248. **Web:**
 249. **Other:**
 250. **Comments:**
 251. **Remarks:**
 252. **Signature:**
 253. **Date:**
 254. **Time:**
 255. **Place:**
 256. **Country:**
 257. **City:**
 258. **State:**
 259. **Zip:**
 260. **Phone:**
 261. **Fax:**
 262. **E-mail:**
 263. **Web:**
 264.

XX
KW
KW
KW

018	Matsumura, T.
XX	
P-N	W. 2100 x 2765 x A2.
XX	

11	200	000	20000
XX			
11	100	000	10000
XX			

(:MMI) :MMI of (No.)

XX With 2000-41214/CT.

Example 1: Page 19, top; Endish.

The present invention relates to a halpin or hammerhead ribozyme, or a derivative thereof, encoding a specific or cell cycle dependent kinase other than cell cycle dependent kinases CKI, p34^{cdc2} and cyclin B1, and consisting of a hammerhead ribozyme and a kinase domain, in which the hammerhead ribozyme is fused to the kinase domain.

of the disease, the response to the therapy is usually limited. Osteosarcoma of the fibroepithelial type of the fibroepithelial type is resistant to chemotherapy and hence is not amenable to treatment.

Fig. 2. Population: 16 B; 1 A; 6 C; 6 G; 5 T; 0 other.

Gentry Match	100, OK;	Sector 16; Hk 21;	Louette, Pa.
Hest Local Similitude	100, OK;	Prec. No., 1,700,022	
Machos	16; conservative	02	Machos

[illegible]

REF: 111 3
 AAAB6777
 AAAB6777 24 AUGUST 1984: 16, 83

```

A*
AAAA6777:
XX
XX
04-10-2000: (first entry)
XX

```

[illegible]

Mammals 1.1.

We (Zimmer & Zittel, 1985; Zittel & Zimmer, 1985)

[illegible][illegible]

Now halrin and hammett ribozyme for inh

Example 1; Page 24; 109pp; English.

the present invention relates to a multiplicity of heteroduplexes, the present invention relates to a multiplicity of heteroduplexes designed to cleave RNA encoding a cyclin or G1-*specific* dependent kinases other than cell cycle dependent kinases (i.e., PNA and cyclin). In the present invention, examples of the cyclin-*specific* kinases are also provided. Examples of the cyclin-*specific* kinases are also provided.

[illegible][illegible][illegible]
$$(b) \quad 1 - q^2 r^2 + (q^2 r^2 + e^2 r^2 + f^2 r^2 + g^2 r^2 + h^2 r^2 + i^2 r^2 + j^2 r^2 + k^2 r^2 + l^2 r^2 + m^2 r^2 + n^2 r^2 + o^2 r^2 + p^2 r^2 + q^2 r^2 + r^2 + s^2 r^2 + t^2 r^2 + u^2 r^2 + v^2 r^2 + w^2 r^2 + x^2 r^2 + y^2 r^2 + z^2 r^2 + 1) r^2$$

AA16.17.21 Standard; INA: 17.165
AA16.17.21; AA16.17.21

ANNALS

$$10.57 \pm 0.11$$

Best Local Similarity: 93.9% Prod. No. 270043
 Matches: 147 Conservative: 72 Mismatches: 17 Indels: 0 Gaps: 0

25 1 acgagatcagagat 15
 ||||| |||||
 10 cgttccttccaaagagat 5

RESULT 14
 AAH75062/2
 10 AAH75062 standard: (RNA) 20 BP.
 XX
 AC AAH75062
 XX
 25 AAT 2000 (first entry)
 XX
 10 PCR primer MH72
 XX
 KM hypercalcaemic crisis: parathyroid hormone-related peptide (PTHrP)
 KM human: human: pcr primer: ss.
 XX
 05 Synthesized
 XX
 10 W020000219 A1
 XX
 25 JAN 1999: 9080 JP04434
 XX
 10 25 JAN 1998: 9080 JP04434
 XX
 10 (CHNS) CHNSAI SEIYAKU KK
 XX
 10 Sato K, Isumori T
 XX
 10 WPI: 2000 117115/10
 XX
 10 Treatment of hypercalcaemic crisis with a substance inhibiting binding
 10 of parathyroid hormone-related peptide to its receptor
 XX
 10 Example 2: Page 69 (2pp) Japanese
 XX
 05 The invention relates to a method of treatment of hypercalcaemic crisis.
 05 A composition for the treatment of hypercalcaemic crisis contains as
 05 active component a substance which inhibits the binding of parathyroid
 05 hormone-related peptide (PTHrP) to its receptor. The inhibitor is used
 05 for the treatment of hypercalcaemic crisis, such as that associated with
 05 a malignant tumour.
 XX
 10 Sequence 20 BP: 7 A: 6 of 4 12 3 13 0 other:

Query Match: 84.8% Score 14.4 Jm 212 Length 20
 Best Local Similarity: 93.9% Prod. No. 270043
 Matches: 147 Conservative: 72 Mismatches: 17 Indels: 0 Gaps: 0

25 1 acgagatcagagat 15
 ||||| |||||
 10 cgttccttccaaagagat 5

RESULT 14
 AAH75062/2
 10 AAH75062 standard: (RNA) 20 BP.
 XX
 AC AAH75062
 XX
 10 1A NIV 2001 (first entry)
 XX
 10 Nucleotide sequence of a primer
 XX
 10 Tissue decomposition inhibitor: parathyroid hormone-related peptide
 XX
 10 experimentally synthesized: hydrophobic: hydrophobic: hydrophobic: hydrophobic

KM granulocyte colony stimulating factor: interleukin-11
 KM leukemia inhibitory factor: soluble (ssr primer): ssr
 XX
 05 Synthesized
 XX
 10 W0200154249 A1
 XX
 10 07 SEP 2001
 XX
 10 10-AUG 2000: 2000WO JP05886
 XX
 10 28-SEP-2000: 2000JP 0052414
 XX
 10 (CHNS) CHNSAI SEIYAKU KK
 XX
 10 Sato H, Isumori T, Onuma E, Sato K
 XX
 10 WPI: 2001-550181/61
 XX
 10 Tissue decomposition inhibitor that prevents parathyroid hormone
 10 associated proteins from binding to its receptor
 XX
 10 Example 1: Page 78 (4pp) Japanese
 XX
 10 The specification describes a tissue decomposition inhibitor, which
 10 comprises a substance that inhibits peptides associated with
 10 parathyroid hormone from binding with their receptor. The method is
 10 used to inhibit tissue decomposition caused by cancer, such as
 10 septal metastasis, heavy extral in part of metastatic part of
 10 treating patients with elevated cytokine (interleukin-6, granulocyte
 10 colony stimulating factor), interleukin-11 and leukemia inhibitory
 10 factor) levels. It may also be used for preventing metastasis caused
 10 by cancer, such as, the present sequence represents a pcr primer used
 10 in the course of the invention.
 XX
 10 Sequence 20 BP: 7 A: 6 of 4 12 3 13 0 other:

Query Match: 84.8% Score 14.4 Jm 212 Length 20
 Best Local Similarity: 93.9% Prod. No. 270043
 Matches: 147 Conservative: 72 Mismatches: 17 Indels: 0 Gaps: 0

25 1 acgagatcagagat 15
 ||||| |||||
 10 cgttccttccaaagagat 5

RESULT 15
 AAH74244/2
 10 AAH74244 standard: (RNA) 20 BP.
 XX
 AC AAH74244
 XX
 10 15-OCT-2001 (first entry)
 XX
 10 PCR primer used to amplify murine cDNA expression and PTHrP and hydro
 10 parathyroid hormone-associated peptide (PTHrP) gene expression
 XX
 10 PCR primer: ss.
 XX
 05 Mus SP
 XX
 10 W0200154725 A1
 XX
 10 02 AUG 2001
 XX
 10 1A-DEC-2000: 2000WO JP08875
 XX
 10 25 JAN 2000: 2000JP 0088044
 XX
 10 (CHNS) CHNSAI SEIYAKU KK
 XX
 10 Sato A, Sato K, Isumori T

[illegible]

and the use of the term "dysphagia" is not useful for the identification of the underlying disorder in the differential diagnosis of the oral disease.

[illegible]

and its treatment directed to the human parathyroid hormone-associated protein (PTHrP). The anti-PTHrP treatment is used in the course of the

The treatment comprises a substance that inhibits binding between parathyroid hormone-related peptide and its receptor.

20 BF; 7 A; 6 C; 4 D; 1; 0 other;

Copyright © 1987
 Score 14.4; 1R 22;
 Post. Lat. Similarity
 93.3%; Prod. No. 2.7e+03;
 Length 20;

[illegible][illegible]

Submitted: September 25, 2002; 21:21:59

Query Match 100.0% Score 16; DB 6; Length 16;
 Post Local Similarity 100.0%; Prod. No. 2; Length 16;
 Matches 16; Conservative 0; Mismatches 0; Gaps 0;

RESULTS

AXI 42667

DEFINITION

ACCESSION

VERSION

KEYWORDS

SCOPES

REFERENCE

ATTACH

TITLE

DESCRIPTION

SEQUENCE

BASES: 100

LENGTH

QUERY MATCH

POST LOCAL SIMILARITY

PRODUCT NO.

LENGTH

MATCHES

CONSERVATIVE

MISMATCHES

GAPS

RESULTS

AXI 42667

DEFINITION

ACCESSION

VERSION

KEYWORDS

SCOPES

REFERENCE

ATTACH

TITLE

DESCRIPTION

SEQUENCE

BASES: 100

LENGTH

QUERY MATCH

POST LOCAL SIMILARITY

PRODUCT NO.

LENGTH

MATCHES

Query Match 100.0% Score 16; DB 6; Length 16;
 Post Local Similarity 100.0%; Prod. No. 2; Length 16;
 Matches 16; Conservative 0; Mismatches 0; Gaps 0;

RESULTS

AXI 42667

DEFINITION

ACCESSION

VERSION

KEYWORDS

SCOPES

REFERENCE

ATTACH

TITLE

DESCRIPTION

SEQUENCE

BASES: 100

LENGTH

QUERY MATCH

POST LOCAL SIMILARITY

PRODUCT NO.

LENGTH

MATCHES

CONSERVATIVE

MISMATCHES

GAPS

RESULTS

AXI 42667

DEFINITION

ACCESSION

VERSION

KEYWORDS

SCOPES

REFERENCE

ATTACH

TITLE

DESCRIPTION

SEQUENCE

BASES: 100

LENGTH

QUERY MATCH

POST LOCAL SIMILARITY

PRODUCT NO.

LENGTH

MATCHES

CONSERVATIVE

MISMATCHES

Query Match 100.0% Score 16; DB 6; Length 16;
 Post Local Similarity 100.0%; Prod. No. 2; Length 16;
 Matches 16; Conservative 0; Mismatches 0; Gaps 0;

RESULTS

AXI 42667

DEFINITION

ACCESSION

VERSION

KEYWORDS

SCOPES

REFERENCE

ATTACH

TITLE

DESCRIPTION

SEQUENCE

BASES: 100

LENGTH

QUERY MATCH

POST LOCAL SIMILARITY

PRODUCT NO.

LENGTH

MATCHES

CONSERVATIVE

MISMATCHES

GAPS

RESULTS

AXI 42667

DEFINITION

ACCESSION

VERSION

KEYWORDS

SCOPES

REFERENCE

ATTACH

TITLE

DESCRIPTION

SEQUENCE

BASES: 100

LENGTH

QUERY MATCH

POST LOCAL SIMILARITY

PRODUCT NO.

LENGTH

MATCHES

CONSERVATIVE

MISMATCHES

FEATURES

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

RESULT 1

Match 19: 81.88% Score 11.41 100.0% Length 200
Best Local Similarity 93.78% Prod. No. 4.20-04
Matches 14: Conserved 10 Mismatches 4 Indels 0 Caps 0

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

REFERENCE

Source: 1. 20
Location/Qualifiers: 20 bp LNA Linear PAT 31 JAN 2002

BASE COUNT

7 a 6 c 4 a 4 c

Indels 0 Caps 0

